Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Unicycive Therapeutics, Inc. (UNCY)
|
Add to portfolio |
|
|
|
| Price: |
$1.98
| | Metrics |
| OS: |
34.8
|
M
| |
-441
|
% ROE
|
| Market cap: |
$68.8
|
M
| |
|
|
|
Net cash:
|
$18.8
|
M
| |
$0.54
|
per share
|
|
EV:
|
$50
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($19.4)
|
M
| |
|
|
|
EBIT
|
($19.4)
|
M
| |
|
|
| EPS |
($1.98)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 1.0 | 0.0 | 0.0 | 0.8 |
| Revenue growth | | | -100.0% | |
| Cost of goods sold | -19.0 | 0.0 | 0.0 | 2.0 |
| Gross profit | 20.0 | 0.0 | 0.0 | -1.2 |
| Gross margin | 2098.8% | | | -146.9% |
| Research and development | 12.4 | 6.1 | 1.0 | |
| General and administrative | 6.6 | 2.9 | 1.0 | 1.2 |
| EBIT | -18.1 | -9.0 | -2.0 | -2.0 |
| EBIT margin | -1898.2% | | | -246.9% |
| Pre-tax income | -18.1 | -10.0 | -2.3 | -2.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -18.1 | -10.0 | -2.3 | -2.2 |
| Net margin | -1898.8% | | | -272.3% |
| |
| Diluted EPS | ($1.20) | ($0.86) | ($0.27) | ($0.27) |
| Shares outstanding (diluted) | 15.1 | 11.7 | 8.5 | 8.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|